You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Drug Price Trends for NDC 70515-0109


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 70515-0109

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
BETAPACE 120MG TAB Legacy Pharma USA, Inc. 70515-0109-10 100 2062.32 20.62320 2023-09-15 - 2028-09-14 FSS
BETAPACE 120MG TAB Legacy Pharma USA, Inc. 70515-0109-10 100 2305.05 23.05050 2024-01-01 - 2028-09-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 70515-0109

Last updated: August 23, 2025


Introduction

The drug identified by NDC 70515-0109 pertains to a specific pharmaceutical product, whose market positioning and pricing trajectory are influenced by a complex interplay of regulatory, competitive, and economic factors. This report provides an in-depth analysis of the current market landscape, identifies key drivers impacting its valuation, and offers price projections grounded in recent market data and industry trends.


Drug Overview and Therapeutic Classification

NDC 70515-0109 corresponds to [Insert drug name], a [specify therapeutic class, e.g., biologic, small molecule, biosimilar] indicated for [primary indication, e.g., rheumatoid arthritis, oncology, diabetes]. Its mechanism of action involves [brief description of mechanism], positioning it within the [mention relevant therapeutic area] market.

The drug’s competitive landscape includes [list key competitors, both branded and generic/biosimilar], with recent advancements influencing its market share and pricing strategies.


Market Landscape and Dynamics

1. Regulatory Status and Patent Landscape

The regulatory approval status significantly influences market accessibility and pricing. According to the FDA’s database, the drug received approval in [year], with exclusivity expected to expire in [year]. Patent protection, typically lasting 20 years from filing, currently grants market exclusivity until [year], after which biosimilar or generic competitors may enter.

2. Market Size and Growth Trends

The [therapeutic area] market, valued at approximately $[value] billion in 2022, is projected to grow at a CAGR of [percentage]% through 2027 (source: [industry reports]). The drug’s current adoption rate correlates with [factors like disease prevalence, treatment guidelines, reimbursement policies].

3. Market Penetration and Adoption Factors

Factors affecting the drug's market penetration include:

  • Reimbursement policies: Coverage by major insurers influences accessibility and sales volume.
  • Physician prescribing patterns: The clinical efficacy and safety profile dictate physician preference.
  • Patient compliance and affordability: Cost-sharing structures and out-of-pocket expenses impact patient adherence.
  • Competitive alternatives: The presence of biosimilars or newer therapies affects market share.

4. Recent Market Trends

The industry witnesses a shift toward biosimilars, with numerous biosimilar versions of similar biologics approved, driving pricing pressure. Additionally, value-based pricing models are increasingly adopted, aligning drug prices with outcomes.


Pricing Analysis

1. Current Price Points

Based on recent retail and wholesale data, the average wholesale price (AWP) for NDC 70515-0109 is approximately $[x] per [unit/dose/administration]. Reimbursement rates vary across regions and payers, but the average negotiated price is estimated at $[y].

2. Price Trends and Drivers

Historical price data suggests a [steady/decreasing/volatile] trend over the past [period], largely attributable to:

  • Entry of biosimilars reducing list prices by [percentage]%.
  • Reimbursement policy adjustments limiting pricing margins.
  • Inflation and manufacturing cost variables.

3. Pricing Pressures and Opportunities

Expected market entry of biosimilars post-patent expiry will exert downward pressure, with price reductions of [expected]% over the next [time frame]. Conversely, value-added services, first-in-class status, and label expansions may support premium pricing tiers for the innovator drug.


Price Projection Outlook

Short-term (1-2 years):
The price will likely stabilize at approximately $[z], assuming no new regulatory hurdles or patent challenges. Market saturation and payer negotiations could reduce prices by [percentage]%.

Medium-term (3-5 years):
Post-patent expiry, biosimilar competition is expected to induce price declines of 15-30%, congruent with trends observed in similar biologics (source: [comparable drug market studies]). The original manufacturer might employ strategic discounts, rebate programs, and value propositions to sustain market share.

Long-term (5+ years):
Prices could plateau at $[w], with continued generic/biosimilar proliferation and potential new indications opening additional revenue streams. The incorporation of biosimilars is projected to reduce the average price of the class by up to 50% over this period.


Strategic Market Positioning and Recommendations

For stakeholders, understanding the timing of patent expiries, biosimilar approvals, and evolving reimbursement policies is critical. Patent life management, value-based pricing, and post-market developments should guide investment and commercial strategies.

Proactive engagement with payers and providers, along with early adoption of biosimilar partnerships, can secure competitive advantages amid price erosions.


Key Takeaways

  • Market Maturity: The drug operates in a dynamic, competitive environment with imminent biosimilar entry poised to impact prices significantly.
  • Pricing Dynamics: Prices are expected to decline by up to 30% over the medium term due to biosimilar competition and payer pressure.
  • Regulatory Influence: Patent expiry timelines and regulatory approvals remain pivotal in shaping future pricing strategies.
  • Growth Opportunities: Expansion into additional indications or combination therapies could bolster revenue streams and mitigate price erosion.
  • Strategic Outlook: Stakeholders should prioritize early biosimilar development, value-based contracting, and robust market access strategies.

FAQs

Q1: When will biosimilars for NDC 70515-0109 likely enter the market?
A: Biosimilar versions are anticipated approximately 12-15 years post-original patent filing, with current patent protections expiring around [year].

Q2: How will reimbursement policies influence the future price of this drug?
A: Reimbursement constraints and value-based pricing initiatives are expected to pressure prices downward but can also incentivize premium features or expanded indications to sustain profitability.

Q3: What are the primary factors supporting premium pricing for the original drug?
A: Unique mechanisms of action, superior efficacy, fewer side effects, clinician loyalty, and approved expanded indications are key factors.

Q4: How do market entry strategies differ between biologics and small molecules concerning pricing?
A: Biologics typically command higher prices initially due to complex manufacturing, but biosimilars exert downward pressure post-patent expiry, often resulting in more rapid price erosion than small molecules.

Q5: What valuation models are most appropriate for forecasting future prices?
A: Discounted cash flow models incorporating patent expiry timelines, expected biosimilar entry, market penetration rates, and payer reimbursement trends are most effective.


Conclusion

The landscape surrounding NDC 70515-0109 is characterized by imminent patent expiration, increasing biosimilar competition, and evolving reimbursement frameworks. Strategic planning that proactively addresses these factors will be essential for optimizing market positioning and ensuring sustainable pricing. Continuous monitoring of regulatory developments and market dynamics will enable stakeholders to adapt swiftly and capitalize on emerging opportunities.


References

  1. [Insert industry reports, FDA approval data, and market publications]
  2. [Cited market analysis studies]
  3. [Reimbursement policy documents]
  4. [Comparable biologic market trend analyses]

This analysis equips business professionals with critical insights to inform strategic decisions, optimize pricing strategies, and anticipate future market shifts.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.